Mortality and Vascular Morbidity in Older Adults With Asymptomatic Versus Symptomatic Peripheral Artery Disease

  • Curt Diehm
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • Jens Rainer Allenberg
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • David Pittrow
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • Matthias Mahn
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • Gerhart Tepohl
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • Roman L. Haberl
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • Harald Darius
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • Ina Burghaus
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....
  • Hans Joachim Trampisch
    From the Department of Internal Medicine/Vascular Medicine, SRH-Klinikum Karlsbad-Langensteinbach, Karlsbad (C.D.); Department of Vascular Surgery, Ruprecht-Karls University of Heidelberg, Heidelberg (J.R.A.); Department of Clinical Pharmacology, Medical Faculty, Technical University, Dresden (D.P.); Department for Clinical Research, Sanofi-Aventis, Berlin (M.M.); Department of Neurology, Hospital Harlaching, Munich (R.L.H.); Department of Medicine I, Vivantes Neukölln Medical Center, Berlin (H.D....

抄録

<jats:p> <jats:bold> <jats:italic>Background—</jats:italic> </jats:bold> Our aim was to assess the mortality and vascular morbidity risk of elderly individuals with asymptomatic versus symptomatic peripheral artery disease (PAD) in the primary care setting. </jats:p> <jats:p> <jats:bold> <jats:italic>Methods and Results—</jats:italic> </jats:bold> This prospective cohort study included 6880 representative unselected patients ≥65 years of age with monitored follow-up over 5 years. According to physician diagnosis, 5392 patients had no PAD, 836 had asymptomatic PAD (ankle brachial index <0.9 without symptoms), and 593 had symptomatic PAD (lower-extremity peripheral revascularization, amputation as a result of PAD, or intermittent claudication symptoms regardless of ankle brachial index). The risk of symptomatic compared with asymptomatic PAD patients was significantly increased for the composite of all-cause death or severe vascular event (myocardial infarction, coronary revascularization, stroke, carotid revascularization, or lower-extremity peripheral vascular events; hazard ratio, 1.48; 95% confidence interval, 1.21 to 1.80) but not for all-cause death alone (hazard ratio, 1.13; 95% confidence interval, 0.89 to 1.43), all-cause death/myocardial infarction/stroke (excluding lower-extremity peripheral vascular events and any revascularizations; hazard ratio, 1.18; 95% confidence interval, 0.92 to 1.52), cardiovascular events alone (hazard ratio, 1.20; 95% confidence interval, 0.89 to 1.60), or cerebrovascular events alone (hazard ratio, 1.33; 95% confidence interval, 0.80 to 2.20). Lower ankle brachial index categories were associated with increased risk. PAD was a strong factor for the prediction of the composite end point in an adjusted model. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusions—</jats:italic> </jats:bold> Asymptomatic PAD diagnosed through routine screening in the offices of primary care physicians carries a high mortality and/or vascular event risk. Notably, the risk of mortality was similar in symptomatic and asymptomatic patients with PAD and was significantly higher than in those without PAD. In the primary care setting, the diagnosis of PAD has important prognostic value. </jats:p>

収録刊行物

  • Circulation

    Circulation 120 (21), 2053-2061, 2009-11-24

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (37)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ